TransTACs have been designed to exploit the rapid co-internalization of transferrin receptor 1, allowing the degradation of various membrane proteins associated with cancer proliferation.
These chimeras provide a novel therapeutic approach by targeting drug-resistant mutations in cancer cells, enabling precise manipulation of membrane proteins for effective treatment.
The study demonstrates the versatility of TransTACs in targeting both native and synthetic membrane proteins, showing promise for enhanced cancer therapies.
TransTACs represent a significant advancement in antibody technology, offering a new strategy for the degradation of specific proteins related to cancer cell growth.
#cancer-therapy #transferrin-receptor #antibody-technology #membrane-protein-degradation #drug-resistance
[
Collection
]
[
|
...
]